Rare protein-altering variants in *ANGPTL7* lower intraocular pressure and protect against glaucoma

Yosuke Tanigawa[1], Michael Wainberg[1], Juha Karjalainen[2,3,4], Tuomo Kiiskinen[4,5],

Susanna Lemmelä[4,5], Joni A. Turunen[6,7], Robert Graham[8], Aki S. Havulinna[4,5], Markus Perola[5],

Aarno Palotie[2,4], FinnGen, Mark J. Daly[2,3,4+] and Manuel A. Rivas[1+]

1. Department of Biomedical Data Science, School of Medicine, Stanford University, Stanford, CA, USA.
2. Program in Medical and Population Genetics and Stanley Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA, USA.
3. Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.
4. Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, Finland.
5. Finnish Institute for Health and Welfare, Helsinki, Finland
6. Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland
7. Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland
8. Maze Therapeutics, San Francisco, CA, USA.
+ Corresponding authors, contributed equally to the work

Protein-altering variants that are protective against human disease provide *in vivo* validation of therapeutic targets. Here we use genotyping data in UK Biobank and FinnGen to conduct a search for protein-altering variants conferring lower intraocular pressure (IOP) and protection against glaucoma. Through protein-altering variant association analysis we find a missense variant in UK Biobank (rs28991009 (MAF=0.8%) genotyped in 81,527 individuals with measured IOP and an independent set of 4,269 glaucoma patients and 251,355 controls) that significantly lowers IOP (β = -0.73 mmHg for heterozygotes, -2.96 mmHg for homozygotes, *P* = 1 x 10^-13) and is associated with 34% reduced risk of glaucoma (*P* = 0.005). In FinnGen, we identify an *ANGPTL7* missense variant at a greater than 50-fold increased frequency in Finland compared with other populations (rs147660927, p.Arg220Cys, MAF Finland = 4.1%), which was genotyped in 5,177 glaucoma patients and 130,461 controls and is associated with 30% lower glaucoma risk (*P* = 1 x 10^-9). We further find three rarer variants in UK Biobank, including a protein-truncating variant, which confer a strong composite lowering of IOP (*P* = 0.002), suggesting the protective mechanism likely resides in the loss of an interaction or function. Our results support inhibition or down-regulation of ANGPTL7 as a therapeutic strategy for glaucoma.

Corresponding authors: Manuel A. Rivas, mrivas@stanford.edu and Mark J. Daly, mjdaly@broadinstitute.org

Introduction

35 Intraocular pressure is currently the sole modifiable risk factor and predictive measure for glaucoma[1,2,3,4] (**Supplementary Figure S1**).Genome-wide association studies(GWAS) have commonly used genetic associations to this endophenotype that exhibits high genetic correlation (rg = 0.71) to glaucoma, as an approach to prioritize genetic variants likely to contribute to disease risk[5]. A total of 53 independent loci have been unequivocally implicated in

40 glaucoma[5]. For these discoveries, like most GWAS results, it has proven challenging to infer the functional consequences of common variant associations beyond cases where protein-altering variants have been directly implicated. Protein-altering variants, generally the strongest-acting genetic variants in medical genetics, include nonsynonymous substitutions and protein-truncating variants, and understanding their functional consequences provides insight

45 into the therapeutic effects of inhibiting or down-regulating the gene in which they reside[6]. Thus, identifying protein-altering variants that confer protection from disease holds particular promise for identifying therapeutic targets.

Here we leverage two cohorts that provide complementarity for glaucoma gene discovery. First, UK Biobank has obtained intraocular pressure (IOP) measurements in approximately 128,000

50 individuals in addition to case-control status for glaucoma from hospital in-patient and verbal questionnaire data in over 500,000 individuals[7,8]. Second, FinnGen has directly genotyped and aggregated disease outcomes in over 135,000 individuals from Finland, an isolated population with recent bottlenecks that offers an unprecedented advantage for studying rare variants in complex diseases[9]. With clinic-based recruitment focused on several areas including

55 ophthalmology, and with 32.4% of the collection above age 70, FinnGen is particularly well-powered for aging-associated endpoints. We therefore conduct targeted association analysis with IOP in UK Biobank (N = 81,534) to identify protein-altering variants that reduce IOP, and test whether those variants, or others in the same genes, also confer protection to glaucoma in FinnGen (5,177 cases and 130,461 controls) and UK Biobank (4,269 cases and

60 251,355 controls not included in the IOP sample). Analysis of an allelic series of protein-altering variants in *ANGPTL7* in 9,446 glaucoma patients and over 350,000 controls identifies a significant lowering effect on IOP and protective association with glaucoma. By analyzing putative loss-of-function variants, we find concordant effect directions with the nonsynonymous substitutions, suggesting that the protective mechanism may reside in the loss of gene function.

65 # Results

Protein-altering variant association analysis

We conducted protein-altering variant association analysis with IOP, as measured via Goldmann-correlated tonometry, in 81,527 British individuals in UK Biobank dataset

(Methods)[10]. Across 41,632 rare (0.01 % < MAF < 1%) protein-altering variants outside of the MHC region with genotyping array data in UK Biobank, we used a generalized linear model implemented in PLINK[11] to scan for variants with IOP-lowering effects. We identified one protein-altering variant significantly associated with lower IOP below a Bonferroni-corrected P value < 1.0×10^{-6}, a nonsynonymous substitution (p.Gln175His) in *ANGPTL7* ($P = 1.47 \times 10^{-13}$, β = -0.200 SD 95% CI: [-0.253, -0.147], -0.73 mHg for heterozygotes, -2.96 mmHg for homozygotes, **Table 1,2**, **Supplementary Figure S2**).

Based on this finding, we assessed whether any additional rare variant associations in *ANGPTL7* were present. We found three additional independent rare protein-altering variants in *ANGPTL7* (MAF < 0.25%) including a premature stop-gain allele (p.Arg177Ter). Collectively, these three variants showed a marginally significant association with lower IOP ($P = 0.0023$, **Table 1**), with the stop-gain allele p.Arg177Ter also showing a marginally significant effect on its own ($P = 0.038$). Genotyping intensity plots and the concordance of genotype calls from array and whole-exome sequencing data were manually inspected to ensure high quality and consistent genotyping (**Supplementary Figure S3, Supplementary Table S1, Methods**) and alleles were confirmed to be independent (pairwise r^2 < 10^{-4} for each, **Supplementary Table S2, Methods**). Using inverse variance weighted meta-analysis method, the combined effect of those four variants are estimated to be -0.19 ([95% CI: -0.23 - -0.14] SD, $P = 3.4 \times 10^{-16}$; -0.67 mmHg [95% CI: -0.85 - -0.49], **Supplementary Figure S4, Supplementary Tables S3-4, Methods**).

Given these findings, we next asked whether any of these putative IOP-lowering genetic variants showed effects consistent with reducing glaucoma risk in an independent set of British individuals that do not have IOP measures (4,269 cases and 251,355 controls). For p.Gln175His in *ANGPTL7*, we estimated that the variant lowers glaucoma risk by 34% ($P = 0.00543$; OR = 0.66 [95% CI: 0.366 - 0.954]). The three additional protein-altering variants did not significantly confer protection against glaucoma (burden test $P = 0.55$), although we expect this to be a result of limited power in the binary case-control setting.

Variant	rsID	HGVSp	MAF	Beta SD [95% CI]	P
1:11252357:A:G	rs200058074	p.Gln136Arg	.054 %	-.038 [-.26, .18]	7.3×10^{-1}
1:11252369:G:A	rs28991002	p.Arg140His	.25 %	-.16 [-.25, -.061]	1.3×10^{-3}
1:11253684:G:T	rs28991009	p.Gln175His	.81 %	-.20 [-.25, -.15]	1.4×10^{-13}
1:11253688:C:T	rs143435072	p.Arg177Ter	.041 %	-.26 [-.51, -.014]	3.8×10^{-2}

Table 1. *ANGPTL7* IOP protein-altering variant association in UK Biobank. Variant includes chromosome, position, reference, and alternate allele (hg19). rsID - the rs identifier of the genetic variant. HGVSp - the HGVS

protein sequence name. MAF - the minor allele frequency in UK Biobank British population. Beta - estimated regression coefficient with 95% confidence intervals. *P* - p-value of association.

Variant	Dosage	rsID	Carrier frequency in UK	Carrier frequency in Finland	N with IOP (UK Biobank)	IOP (mmHg) [95% CI]	OR for glaucoma
Gln175His	Gln/His	rs28991009	1.43%	0.24%	1355	-0.73 [-0.95, -0.52] ***	0.66 **
Gln175His	His/His		0.01%	NA	5	-2.95 [-6.43, 0.530] .	NS
Arg177Ter	Arg/Ter	rs143435072	0.07%	NA	62	-0.94 [-1.93, 0.0445] .	NS
Arg140His	Arg/His	rs28991002	0.51%	0.35%	427	-0.48 [-0.86, -0.10] *	NS
Gln136Arg	Gln/Arg	rs200058074	0.11%	NA	80	-0.21 [-1.08, 0.66]	NS
Arg220Cys	Arg/Cys	rs147660927	NA	7.82%	NA	NA	0.72 ***
Arg220Cys	Cys/Cys		NA	0.21%	NA	NA	0.47 .

Significant codes: 0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1

Table 2. *ANGPTL7* allelic series summary. Variant: HGVSp amino acid nomenclature. Dosage - genotype of individuals. rsID - rs identifier. Carrier frequency in UK - carrier frequency in UK Biobank for the respective genotype dosage. Carrier frequency in Finland - carrier frequency in FinnGen for the respective genotype dosage. N with IOP (UK Biobank) - number of individuals in UK Biobank with intraocular pressure measurements corresponding to the genotype dosage. IOP (mmHg) [95% CI] - unstandardized estimates of effect size on intraocular pressure measurements (NB: standardized estimated effect sizes may have lower p-values due to normalization procedure). OR for glaucoma - estimate odds ratio on glaucoma risk for the respective genotype dosage. NS non-significant (p > 0.1).

Independent Finnish-enriched missense allele in *ANGPTL7*

We then sought evidence from the FinnGen dataset that either the same or novel Finnish-enriched protein-altering variants would confirm the association of *ANGPTL7* with protection from glaucoma. This additional *ANGPTL7* association data, obtained in 5,177 glaucoma patients and 130,461 controls, provided strong support that protein-altering variants in *ANGPTL7* protect against glaucoma (case definitions described in **Supplementary Table S5**). Specifically, we found that the p.Gln175His substitution has nominal evidence of association (*P* = 0.031, OR = 0.49) despite the variant only being present at a minor allele frequency of 0.1% in this Finnish cohort (8-fold depleted compared to UK Biobank). The remaining protein-altering

variants in *ANGPTL7* tested in UK Biobank were not found in the FinnGen dataset. Confirmation of an *ANGPTL7* effect on glaucoma risk was seen in data from an independent Finnish-specific
120   protein-altering nonsynonymous substitution, p.Arg220Cys, which was strongly associated with protection from glaucoma (P = 1.0x10^{-9}, OR = 0.72 [95% CI: 0.64 - 0.80], **Supplementary Figure S5**). Of note, this observation is advantaged by the property that p.Arg220Cys is found at a greater than 50-fold increased frequency in Finland compared with other populations[12], reinforcing the value of isolated, bottlenecked populations in which the allele frequency
125   spectrum is intensely concentrated on the minority of variants passing through the bottleneck.

While registry-based diagnoses in FinnGen do not yet contain detailed ophthalmologic records, a subset of 2695 glaucoma patients had been recorded as having primary open-angle glaucoma (POAG). In this sub-group a stronger effect was observed (OR=0.68) versus those glaucoma cases without a definitive record of POAG (OR=0.77 [95% CI: 0.67 - 0.88]), reminiscent of the
130   stronger risk effects seen at the myocilin (*MYOC*) gene and other established genes in the POAG subgroup. Given the Finnish enrichment of the known strong glaucoma risk allele, p.Gln368Ter, in *MYOC* (MAF in Finland = 0.3%, MAF in Non-Finnish European = 0.16%, reference sequence: NM_00026), we next asked whether carriers have risk reduced if they carry *ANGPTL7* p.Arg220Cys. In FinnGen, we estimate that 7.7% of individuals carriers for
135   *MYOC* p.Gln368Ter variant are POAG cases in comparison to 2% for non-carriers. In the presence of *ANGPTL7* p.Arg220Cys, only 1.3% of individuals are POAG cases, and only 1 of 70 (1.4%) who carry both *MYOC* risk and *ANGPTL7* protective variants were POAG cases (**Supplementary Table S6**). This suggests *ANGPTL7* protection extends to the *MYOC* risk group but the small counts preclude any definitive statement regarding interaction - given the
140   limited number of double-carriers, larger case-control series are needed to refine our understanding as to whether *ANGPTL7* p.Arg220Cys variant modifies the glaucoma risk conferred by p.Gln368Ter in *MYOC*.

Access to genotype data in over 300,000 individuals from the UK and 135,000 from the Finnish group enabled us to identify rare protein-altering homozygotes. In UK Biobank we found 28
145   individuals homozygous for the 175His allele, consistent with Hardy-Weinberg expectation (n=22.6), where we estimated a 2.96 mm Hg drop in IOP compared to the mean IOP levels. Furthermore, the oldest reached the age of 80 and one of the 28 died (age 65). In FinnGen we found 268 individuals homozygous for the 220C allele, the oldest reached the age of 98, with no depletion of homozygotes compared with Hardy-Weinberg equilibrium expectation. There was
150   no significant association of the homozygous genotype with a decreased lifespan. Together this indicates that having two copies with 175His or 220Cys in *ANGPTL7* is compatible with normal lifespan. To assess the potential impacts of those protein-truncating variants on reproductive fitness we assessed the association of p.Gln175His with the number of live births and number of children fathered and found no significant association (P > 0.05/4, **Supplementary Table S7**).
155   Hence, we did not find any severe medical consequences that would be of obvious concern in developing a therapeutic to mimic the effect of these alleles.

The combined significance of *ANGPTL7* protein-altering variants across more than 435,000 samples tested is $P = 3.4 \times 10^{-16}$ for IOP and $P = 1.9 \times 10^{-11}$ for glaucoma using inverse-variance weighted method (**Supplementary Figure S6**).

Transcript and protein expression

ANGPTL7, a five-exon protein-coding gene, encodes the Angiopoietin-related protein 7, which is expressed in several human tissues including the trabecular meshwork, cornea and retina [13–15]. Recently, *ANGPTL7* overexpression in primary human trabecular meshwork cells was found to alter the expression of relevant trabecular meshwork proteins of the extracellular matrix, including fibronectin, collagens type I, IV, and V, myocilin, versican, and MMP1, and ANGPTL7 protein was increased as the disease progressed in POAG beagle dogs[13]. We examined proteomics expression data in normal tissues and cell lines from ProteomicsDB and MOPED[16,17] and found vitreous humor tissue-specific expression of ANGPTL7 (log10 ppm = 1, **Supplementary Figure S7**). These data suggest that the eye is the relevant tissue type in understanding the functional consequences of the variants discovered in this study. Further work is dissecting the role of *ANGPL7* in all possible cell types in the eye is warranted.

Discussion

This study establishes strong genetic evidence for the involvement of *ANGPTL7* in glaucoma risk in which a powerful allelic series, including all low-frequency nonsynonymous substitutions and a single premature stop-gain substitution, is conclusively associated with reduced disease risk and endophenotype-lowering effects. Increasing evidence is associating ANGPTL proteins to cardiometabolic phenotypes[18–22]. Although it has been recently proposed that ANGPTL7 levels are increased in obesity and reduced after physical exercise, we do not observe any evidence of genetic association in either UK Biobank or FinnGen to support this hypothesis[23]. In the context of the other established variants in glaucoma, including the protein-truncating variants in *MYOC*, p.Gln175His and the 57-fold Finnish enriched p.Arg220Cys variant in *ANGPTL7* exert a comparable protective effect. Because of the strong protective effect associated with the *ANGPTL7* coding variants, studies of ANGPTL7 inhibition and the specific action of these variant proteins should be useful in understanding the mechanism by which protection to glaucoma disease occurs and whether this reveals a promising therapeutic opportunity similar to that which has been realized from the examples of PCSK9, *APOC3* and cardiovascular disease[24–26]. The phenotype and longevity profile of *ANGPTL7* homozygotes suggest that this is likely to be a safe strategy for therapeutic intervention.

Acknowledgments

Author information

Author contributions

M.A.R. and M.J.D. conceived and designed the study. M.P. designed the FinnGen preparatory project in collaboration with A.P and M.J.D. M.A.R., Y.T., J.K., and M.J.D. carried out the

220 statistical and computational analyses. M.A.R., Y.T., J.K., T.K., J.A.T., and M.J.D. carried out quality control of the data. The manuscript was written by M.A.R., Y.T., and M.J.D.; and revised by all the co-authors. All co-authors have approved of the final version of the manuscript.

Competing financial interests

Robert Graham is an employee of MazeTx.

225

Data availability:

Data is displayed in the Global Biobank Engine (https://biobankengine.stanford.edu). Analysis scripts and notebooks are available on GitHub at https://github.com/rivas-lab/ANGPTL7.

References

1.   Cantor, L. B. Brimonidine in the treatment of glaucoma and ocular hypertension.

230   *Therapeutics and Clinical Risk Management* **2**, 337–346 (2006).

2.   Kass, M. A. *et al.* The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. *Arch. Ophthalmol.* **120**, 701–13; discussion 829–30 (2002).

3.   Kazemian, P., Lavieri, M. S., Van Oyen, M. P., Andrews, C. & Stein, J. D. Personalized

235   Prediction of Glaucoma Progression Under Different Target Intraocular Pressure Levels Using Filtered Forecasting Methods. *Ophthalmology* **125**, 569–577 (2018).

4.   Group, T. J. A. of M. D. in G. (jamdig) C. & The Japanese Archive of Multicentral Database in Glaucoma (JAMDIG) construction group. A novel method to predict visual field progression more accurately, using intraocular pressure measurements in glaucoma

240   patients. *Scientific Reports* **6**, (2016).

5.   MacGregor, S. *et al.* Genome-wide association study of intraocular pressure uncovers new pathways to glaucoma. *Nat. Genet.* **50**, 1067–1071 (2018).

6.   Leshchiner, E. S. *et al.* Small-molecule inhibitors directly target CARD9 and mimic its protective variant in inflammatory bowel disease. *Proc. Natl. Acad. Sci. U. S. A.* **114**,

245   11392–11397 (2017).

7.   Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* **562**, 203–209 (2018).

8.   DeBoever, C. *et al.* Medical relevance of protein-truncating variants across 337,205 individuals in the UK Biobank study. *Nat. Commun.* **9**, 1612 (2018).

250   9.   Lim, E. T. *et al.* Distribution and medical impact of loss-of-function variants in the Finnish founder population. *PLoS Genet.* **10**, e1004494 (2014).

10. Chan, M. P. Y. *et al.* Associations with Intraocular Pressure in a Large Cohort: Results from the UK Biobank. *Ophthalmology* **123**, 771–782 (2016).

11. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer

255   datasets. *Gigascience* **4**, 7 (2015).

12. Lek, M. *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).

13. Comes, N., Buie, L. K. & Borrás, T. Evidence for a role of angiopoietin-like 7 (ANGPTL7) in extracellular matrix formation of the human trabecular meshwork: implications for

260   glaucoma. *Genes Cells* **16**, 243–259 (2011).

14. Santulli, G. Angiopoietin-like proteins: a comprehensive look. *Front. Endocrinol.* **5**, 4 (2014).

15. Kuchtey, J. *et al.* Angiopoietin-like 7 secretion is induced by glaucoma stimuli and its concentration is elevated in glaucomatous aqueous humor. *Invest. Ophthalmol. Vis. Sci.* **49**,

265   3438–3448 (2008).

16. Kolker, E. *et al.* MOPED: Model Organism Protein Expression Database. *Nucleic Acids Res.* **40**, D1093–9 (2012).

17. Schmidt, T. *et al.* ProteomicsDB. *Nucleic Acids Res.* **46**, D1271–D1281 (2018).

18. Musunuru, K. & Kathiresan, S. Cardiovascular endocrinology: Is ANGPTL3 the next PCSK9? *Nat. Rev. Endocrinol.* **13**, 503–504 (2017).

19. Musunuru, K. *et al.* Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia. *N. Engl. J. Med.* **363**, 2220–2227 (2010).

20. Gusarova, V. *et al.* Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes. *Nat. Commun.* **9**, 2252 (2018).

21. Clapham, K. R. *et al.* A null mutation in ANGPTL8 does not associate with either plasma glucose or type 2 diabetes in humans. *BMC Endocr. Disord.* **16**, 7 (2016).

22. Peloso, G. M. *et al.* Association of low-frequency and rare coding-sequence variants with blood lipids and coronary heart disease in 56,000 whites and blacks. *Am. J. Hum. Genet.* **94**, 223–232 (2014).

23. Abu-Farha, M. *et al.* Plasma and adipose tissue level of angiopoietin-like 7 (ANGPTL7) are increased in obesity and reduced after physical exercise. *PLoS One* **12**, e0173024 (2017).

24. Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G. & Tybjærg-Hansen, A. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease. *N. Engl. J. Med.* **371**, 32–41 (2014).

25. TG and HDL Working Group of the Exome Sequencing Project, National Heart, Lung, and Blood Institute *et al.* Loss-of-function mutations in APOC3, triglycerides, and coronary disease. *N. Engl. J. Med.* **371**, 22–31 (2014).

26. Cohen, J. C., Boerwinkle, E., Mosley, T. H., Jr & Hobbs, H. H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N. Engl. J. Med.* **354**, 1264–1272 (2006).

27. Tanigawa, Y. *et al.* Components of genetic associations across 2,138 phenotypes in the UK Biobank highlight novel adipocyte biology. *bioRxiv* 442715 (2019). doi:10.1101/442715

28. McCarthy, M. & O'Brien, E. McCarthy Group Front page. *McCarthy Group* (2018). Available

at: http://mccarthy.well.ox.ac.uk/. (Accessed: 20th May 2019)

295   29. Van Hout, C. V. *et al.* Whole exome sequencing and characterization of coding variation in

49,960 individuals in the UK Biobank. *bioRxiv* 572347 (2019). doi:10.1101/572347

Methods

Genome-wide association analysis in UK Biobank

For British individuals (n = 337,151) in UK Biobank as described elsewhere[8], we applied
300   genome-wide association analysis for directly genotyped variants were applied to
Goldmann-correlated intraocular pressure described more detailed earlier[10] (right, UK Biobank
Field ID 5255, Global Biobank Engine phenotype ID: INI5255) and glaucoma (Global Biobank
Engine phenotype ID: HC276), using generalized linear model association analysis
implemented in PLINK v2.00aLM (2 April 2019) with age, sex, types of genotyping array, and
305   the first 4 genotype principal components as described elsewhere[11,27]. The glaucoma phenotype
was previously defined as a part of "high confidence" disease outcome phenotypes by
combining disease diagnoses (UK Biobank Field ID 41202) from the UK National Health Service
Hospital Episode Statistics (ICD10 codes: H40.[0-6,8,9], H42.8, and Q15.0) with self-reported
non-cancer diagnosis questionnaire (UK Biobank Field ID 20002)[8].

310

Genotyping quality control in UK Biobank

Manual inspection of intensity plots

For the identified rare (0.01 % < MAF < 1%) protein-altering variants in *ANGPTL7* (reference
sequence: NM_021146), we generated and inspected intensity plots with McCarthy Group's
ScatterShot using "UKB - All Participants" module[28].

315

Variant-calling consistency analysis

For individuals with whole-exome sequencing data (n = 49,960), we extracted the genotype
calls of coding variants in *ANGPTL7* using PLINK v2.00aLM (2 April 2019) and compared the
consistency between array-genotyped dataset and whole-exome sequencing dataset[11,29].

Independence analysis of alleles

Pairwise r^2 computation within British individuals in UK Biobank

We computed pairwise r^2 for the identified rare protein-altering variants in *ANGPTL7* within British individuals in UK Biobank using PLINK v1.90b6.7 64-bit (2 Dec 2018) with --ld <variant_ID_1> <variant_ID_1> hwe-midp subcommand[11].

Number of individuals with the combination of genotypes in UK Biobank

Using the extracted genotype calls from for the identified rare protein-altering variants in *ANGPTL7* (see Variant-calling consistency analysis section), we counted the number of British individuals by the combination of genotypes. We computed the expected number of individuals under Hardy-Weinberg equilibrium model and the independence assumption:

- The expected frequencies of REF/REF, REF/ALT, and ALT/ALT carriers are $(1 - AF)^2$, 2 x $AF(1-AF)$, and AF^2, respectively.
- The expected genotyping rate is independently estimated by the observed genotyping rate for each variant.
- The expected frequency of the combination of genotypes is computed under the independent assumption among alleles

Combined effect size estimates of rare protein-altering variants

Using the inverse-variance method for fixed-effects model implemented in R meta package, we performed a meta-analysis of the estimated effect sizes (BETAs) of protein-altering variants on intraocular pressure and glaucoma. For glaucoma, the results are reported as odds ratio. 95% confidence intervals are reported for IOP and glaucoma.

Association analysis with reproductive fitness

Using the number of live births (UK Biobank Field ID: 2734, Global Biobank Engine phenotype ID: INI2734) and the number of children fathered (UK Biobank Field ID: 2405, Global Biobank Engine phenotype ID: INI2405), we performed association analysis for the four identified protein-altering variants using R script with age, types of genotyping array, and the first 4 genotype principal components as covariates.

Homozygous carrier analysis

For UK Biobank British individuals, we extracted the genotype calls with PLINK v2.00aLM (2 April 2019) and identified homozygous carrier of 175H allele[11]. We examined the year of birth (UK Biobank Field ID 34) and age at death (UK Biobank Field ID 40007)[7].

Supplementary Tables and Figures

Supplementary Figure S1. Phenotype distribution of Intraocular pressure stratified by glaucoma disease status displayed as a Tukey's box plot. The middle bold horizontal line represents the median, the lower and upper hinges show the first and third quartiles, the lower and upper whiskers represent 1.5 * interquartile range from the hinges. The data points beyond whiskers are plotted individually.

Supplementary Figure S2. The protein-altering variant GWAS QQ plot for intraocular pressure. The variants outside of MHC region with 0.01 % < MAF < 1% are included in the analysis.

A

B

360

C

D

Supplementary Figure S3. The intensity plots for *ANGPTL7* protein-altering variants with 0.01 % < MAF < 1%. **(A)** rs200058074 (p.Gln136Arg). **(B)** rs28991002 (p.Arg140His). **(C)** rs28991009 (p.Gln175His). **(D)** rs143435072 (p.Arg177Ter)

365 **Supplementary Table S1**. Consistency of the genotype call for four protein-altering variants in *ANGPTL7* between genotyping array and exome sequencing data. Variant including chromosome, position, reference, and alternate allele (hg19), the rs identifier of the genetic variant (rsID), consequence of the variation (Consequence), genotype call from array (Array) and exome data (Exome), and the number of individuals (N). Inconsistent variant calls are
370 highlighted in bold font.

Variant	rsID	Consequence	Array	Exome	N
1:11252357:A:G	rs200058074	p.Gln136Arg	A/G	A/G	42
1:11252357:A:G	rs200058074	p.Gln136Arg	A/A	A/A	49837
1:11252357:A:G	rs200058074	p.Gln136Arg	NA	A/G	1
1:11252357:A:G	rs200058074	p.Gln136Arg	NA	A/A	29
1:11252369:G:A	rs28991002	p.Arg140His	A/A	A/A	1
1:11252369:G:A	rs28991002	p.Arg140His	G/A	G/A	218
1:11252369:G:A	rs28991002	p.Arg140His	**G/A**	**G/G**	**1**
1:11252369:G:A	rs28991002	p.Arg140His	G/G	G/G	49,663
1:11252369:G:A	rs28991002	p.Arg140His	NA	G/G	26
1:11253684:G:T	rs28991009	p.Gln175His	T/T	T/T	4
1:11253684:G:T	rs28991009	p.Gln175His	G/T	G/T	720
1:11253684:G:T	rs28991009	p.Gln175His	G/G	G/G	49,093
1:11253684:G:T	rs28991009	p.Gln175His	NA	G/T	1
1:11253684:G:T	rs28991009	p.Gln175His	NA	G/G	91
1:11253688:C:T	rs143435072	p.Arg177Ter	C/T	C/T	41
1:11253688:C:T	rs143435072	p.Arg177Ter	**C/T**	**C/C**	**1**
1:11253688:C:T	rs143435072	p.Arg177Ter	C/C	C/C	49,857
1:11253688:C:T	rs143435072	p.Arg177Ter	NA	C/C	10

Supplementary Table S2. Number of individuals stratified by genotype of rare (0.01% < MAF < 1%) protein-altering variants in *ANGPTL7*. The combination of genotypes is shown in the first four columns (rs200058074, rs28991002, rs28991009, and rs143435072) as well as the number of British individuals with the genotype combination in UK Biobank (n_observed). The expected number of individuals are computed under Hardy-Weinberg equilibrium model and the independence assumption (n_expected, Method).

rs200058074	rs28991002	rs28991009	rs143435072	n_observed	n_expected
A/A	G/G	G/G	C/C	328,492.00	329,401.21
A/A	G/G	G/T	C/C	5,395.00	5,390.72
A/A	G/A	G/G	C/C	1,693.00	1,672.69
A/A	G/G	NA	C/C	471.00	470.71
A/G	G/G	G/G	C/C	356.00	353.03
A/A	G/G	G/G	C/T	270.00	267.80
A/A	NA	G/G	C/C	194.00	192.47
NA	G/G	G/G	C/C	192.00	188.77
A/A	G/G	G/G	NA	37.00	38.13
A/A	G/G	T/T	C/C	28.00	22.06
A/A	G/A	G/T	C/C	8.00	27.37
A/G	G/G	G/T	C/C	4.00	5.78
A/A	NA	G/T	C/C	2.00	3.15
A/A	G/A	G/G	NA	2.00	0.19
A/A	G/G	NA	C/T	2.00	0.38
NA	G/A	G/G	C/C	1.00	0.96
A/A	A/A	G/G	C/C	1.00	2.12
A/A	G/A	G/G	C/T	1.00	1.36
A/A	G/G	G/T	C/T	1.00	4.38
A/G	G/G	NA	C/C	1.00	0.50

A

B

Supplementary Figure S4: The combined effect size estimates of rare protein-altering variants. The estimates of effect size on unstandardized intraocular pressure measurements (IOP [mmHg]) and normalized intraocular pressure measurements (SD[IOP]) are shown for the four protein-altering variants in *ANGPTL7*. The combined effect size estimate is summarized using inverse-variance method under the fixed effect model (Methods).

Supplementary Table S3. The combined effect size estimates of rare protein-altering variants. The estimates of effect size on normalized intraocular pressure measurements (SD [IOP]) and their 95% confidence interval (95% CI) are shown for the four protein-altering variants in *ANGPTL7*. The combined effect size estimate is summarized using inverse-variance method under the fixed effect model (Methods). %W (fixed) column indicates the relative weights used in the fixed effect model. The bottom right cell indicates the P-value of combined effect size model.

Variant	SD (IOP)	95% CI	%W(fixed)
Gln175His	-0.2003	[-0.2534; -0.1471]	70.5
Arg177Ter	-0.2626	[-0.5107; -0.0144]	3.2
Arg140His	-0.1555	[-0.2502; -0.0607]	22.1
Gln136Arg	-0.0380	[-0.2564; 0.1804]	4.2
Fixed effect model	-0.1856	[-0.2302; -0.1410]	P-value: 3.4×10^{-16}

Supplementary Table S4. The combined effect size estimates of rare protein-altering variants. The estimates of effect size on unstandardized intraocular pressure measurements (IOP [mmHg]) and their 95% confidence interval (95% CI) are shown for the four protein-altering variants in *ANGPTL7*. The combined effect size estimate is summarized using inverse-variance method under the fixed effect model (Methods). %W (fixed) column indicates the relative weights used in the fixed effect model. The bottom right cell indicates the P-value of combined effect size model.

Variant	IOP (mmHg)	95% CI	%W(fixed)
Gln175His	-0.7430	[-0.9547; -0.5314]	70.5
Arg177Ter	-0.9444	[-1.9334; 0.0445]	3.2
Arg140His	-0.4816	[-0.8593; -0.1039]	22.1
Gln136Arg	-0.2078	[-1.0785; 0.6630]	4.2
Fixed effect model	-0.6694	[-0.8471; -0.4917]	P-value: 1.6×10^{-13}

Supplementary Table S5: Glaucoma definitions in FinnGen. ICD-codes are used in the Finnish hospital discharge and cause-of-death registries. ATC-codes are used in the Social Insurance Institution prescription drug purchase registry. All endpoint definitions in the FinnGen phenome-wide association analysis are available online (https://www.finngen.fi/fi/node/68).

Phenotype name	ICD-10	ICD-9	ICD-8	ICD-8 exclude	ATC (drug purchases)
Glaucoma (broad definition, combination of all the subphenotypes below)	Any of the below	Any of the below	Any of the below		S01EA
Glaucoma suspect	H40.0	365.0	375.97		
Primary open-angle glaucoma	H40.1	365.1	375.1[0-3]	375.11	
Primary angle-closure glaucoma	H40.2	365.2	375.00|375.11		
Glaucoma secondary to eye trauma	H40.3	365.6E			
Glaucoma secondary to eye inflammation	H40.4	365.6F|365.6B	364.01		
Glaucoma secondary to other eye disorders	H40.5	365.5|365.6A			
Glaucoma secondary to drugs	H40.6	365.3A			
Other and unspecified glaucoma	H40.[8-9]	365.6X|365.6C|365.[8-9]	375.2|375.9	375.97	
Glaucoma in diseases classified elsewhere	H42	365.4A			
Use of antiglaucoma preparations and miotics					S01EA

Supplementary Figure S5: Phenome-wide association analysis of p.R220C in FinnGen. -log10(P-value) is displayed in y-axis. Disease endpoints grouped by disease categories are displayed on the x-axis. Highlighted associations with *P* < 0.001 are shown.

Supplementary Table S6. FinnGen summary of *MYOC* p.Gln168Ter and *ANGPTL7* p.Arg220Cys carriers in primary open glaucoma cases.

Numbers of POA Glaucoma cases/controls by genotype:

     ANGPTL7

    wt .   R220C+

MYOC- 2,499/119,192 = 2.0% .   146/10,570 = 1.3%

MYOC+ 49/630 = 7.7% . 1/69 = 1.4%

415

Supplementary Table S7. *ANGPTL7* protein-altering variant association with reproductive fitness, (A) the number of live births and (B) the number of children fathered. Variant includes chromosome, position, reference, and alternate allele (hg19). rsID - the rs identifier of the genetic variant. HGVSp - the HGVS protein sequence name. MAF - the minor allele frequency in UK Biobank British population. Beta - estimated regression coefficient with 95% confidence intervals. P - p-value of association.

A. Number of live births

Variant	rsID	HGVSp	MAF	Dosage	Beta [95% CI]	*P*
1:11252357:A:G	rs200058074	p.Gln136Arg	.054 %	Gln/Arg	0.089 [-0.064, 0.24]	0.26
1:11252369:G:A	rs28991002	p.Arg140His	.25 %	Arg/His	0.29 [-1.9, 2.5]	0.80
1:11253684:G:T	rs28991009	p.Gln175His	.81 %	Gln/His	-0.0076 [-0.050, 0.035]	0.72
				His/His	0.23 [-0.48, 0.93]	0.52
1:11253688:C:T	rs143435072	p.Arg177Ter	.041 %	Arg/Ter	0.2 [0.021, 0.38]	0.029

B. Number of children fathered

Variant	rsID	HGVSp	MAF	Dosage	Beta [95% CI]	*P*
1:11252357:A:G	rs200058074	p.Gln136Arg	.054 %	Gln/Arg	0.0064 [-0.19, 0.21]	0.95
1:11252369:G:A	rs28991002	p.Arg140His	.25 %	Arg/His	0.0030 [-0.081, 0.087]	0.94
1:11253684:G:T	rs28991009	p.Gln175His	.81 %	Gln/His	-0.0052 [-0.054, 0.044]	0.83
				His/His	0.41 [-0.17, 0.98]	0.16
1:11253688:C:T	rs143435072	p.Arg177Ter	.041 %	Arg/Ter	-0.052 [-0.27, 0.17]	0.64

Supplementary Figure S6: The combined effect size estimates of rare protein-altering variants. The estimates of effect size (odds ratio, OR) on glaucoma is shown in log scale for the five protein-altering variants in *ANGPTL7*. The combined effect size estimate is summarized using inverse-variance method under the fixed effect model and 95% confidence intervals are shown (Methods).

Supplementary Figure S7: Protein expression in normal tissues and cell lines from ProteomicsDB and MOPED for ANGPTL7

Supplementary Note

FinnGen

FinnGen consists of the following people:

430

Steering Committee

Aarno Palotie	University of Helsinki / FIMM
Mark Daly	University of Helsinki / FIMM

Pharma

Howard Jacob	Abbvie
Athena Matakidou	Astra Zeneca
Heiko Runz	Biogen
Sally John	Biogen
Robert Plenge	Celgene
Julie Hunkapiller	Genentech
Meg Ehm	GSK
Dawn Waterworth	GSK
Caroline Fox	Merck
Anders Malarstig	Pfizer
Kathy Klinger	Sanofi
Kathy Call	Sanofi

UH & Biobanks

Tomi Mäkelä	University of Helsinki / FIMM
Jaakko Kaprio	University of Helsinki / FIMM
Petri Virolainen	Auria BB / Univ. of Turku /VSSHP
Kari Pulkki	Auria BB / Univ. of Turku /VSSHP
Terhi Kilpi	THL Biobank (BB) / THL
Markus Perola	THL Biobank (BB) / THL
Jukka Partanen	Finnish Red Cross Blood Service/FHRB
Anne Pitkäranta	HUS/Univ Hosp Districts
Riitta Kaarteenaho	Borealis BB/Univ. of Oulu/PPSHP
Seppo Vainio	Borealis BB/Univ. of Oulu/PPSHP
Kimmo Savinainen	Tampere BB/Univ Tampere/PSHP
Veli-Matti Kosma	Eastern Finland BB/UEF/PSSHP
Urho Kujala	Central Finland BB /UJy/KSSHP

435

440

445

450

455

460

Scientific Committee

Pharma

Jeff Waring	Abbvie
Bridget Riley-Gillis	AbbVie
Athena Matakidou	Astra Zeneca
Heiko Runz	Biogen
Jimmy Liu	Biogen
Shameek Biswas	Celgene
Julie Hunkapiller	Genentech
Dawn Waterworth	GSK
Meg Ehm	GSK
Josh Hoffman	GSK
Dorothee Diogo	Merck
Caroline Fox	Merck
Anders Malarstig	Pfizer
Catherine Marshall	Pfizer
Xinli Hu	Pfizer
Kathy Call	Sanofi
Kathy Klinger	Sanofi

465

470

475

UH & Biobanks

Samuli Ripatti	University of Helsinki / FIMM
Johanna Schleutker	Auria BB / Univ. of Turku /VSSHP
Markus Perola	THL Biobank (BB) / THL
Tiina Wahlfors	Finnish Red Cross Blood Service/FHRB
Olli Carpen	HUS/Univ Hosp Districts
Johanna Myllyharju	Borealis BB/Univ. of Oulu/PPSHP
Johannes Kettunen	Borealis BB/Univ. of Oulu/PPSHP
Reijo Laaksonen	Tampere BB/Univ Tampere/PSHP
Arto Mannermaa	Eastern Finland BB/UEF/PSSHP
Juha Paloneva	Central Finland BB /UJy/KSSHP
Urho Kujala	Central Finland BB /UJy/KSSHP

480

485

490

Clinical Groups

Neurology Group

Hilkka Soininen	LEAD: Kuopio
Valtteri Julkunen	Kuopio

495	Anne Remes	Oulu
	Reetta Kälviäinen	Kuopio
	Mikko Hiltunen	Kuopio
	Jukka Peltola	Tampere
	Pentti Tienari	Helsinki
500	Juha Rinne	Turku
	Adam Ziemann	AbbVie
	Jeffrey Waring	AbbVie
	Sahar Esmaeeli	AbbVie
	Nizar Smaoui	AbbVie
505	Anne Lehtonen	AbbVie
	Susan Eaton	Biogen
	Heiko Runz	Biogen
	Sanni Lahdenperä	Biogen
	Janet van Adelsberg	Celgene
510	Shameek Biswas	Celgene
	John Michon	Genentech
	Geoff Kerchner	Genentech
	Julie Hunkapiller	Genentech
	Natalie Bowers	Genentech
515	Edmond Teng	Genentech
	John Eicher	Merck
	Vinay Mehta	Merck
	Padhraig Gormley	Merck
	Kari Linden	Pfizer
520	Christopher Whelan	Pfizer
	Fanli Xu	GSK
	David Pulford	GSK

Gastroenterology Group

	Martti Färkkilä LEAD:	Helsinki
525	Sampsa Pikkarainen	HUS
	Airi Jussila	Tampere
	Timo Blomster	Oulu
	Mikko Kiviniemi	Kuopio
	Markku Voutilainen	Turku
530	Bob Georgantas	AbbVie
	Graham Heap	AbbVie
	Jeffrey Waring	AbbVie
	Nizar Smaoui	AbbVie
	Fedik Rahimov	AbbVie
535	Anne Lehtonen	AbbVie

Keith Usiskin	Celgene
Tim Lu	Genentech
Natalie Bowers	Genentech
Danny Oh	Genentech
540 John Michon	Genentech
Vinay Mehta	Merck
Dermot Reilly	Merck
Kirsi Kalpala	Pfizer
Melissa Miller	Pfizer
545 Xinli Hu	Pfizer
Linda McCarthy	GSK

Rheumatology Group

Kari Eklund	LEAD:Helsinki
Antti Palomäki	Turku
550 Pia Isomaki	Tampere
Laura Pirilä	Turku
Oili Kaipiainen-Seppänen	Kuopio
Johanna Huhtakangas	Oulu
Bob Georgantas	AbbVie
555 Jeffrey Waring	AbbVie
Fedik Rahimov	AbbVie
Apinya Lertratanakul	AbbVie
Nizar Smaoui	AbbVie
Anne Lehtonen	AbbVie
560 David Close	AstraZeneca
Marla Hochfeld	Celgene
Natalie Bowers	Genentech
John Michon	Genentech
Dorothee Diogo	Merck
565 Vinay Mehta	Merck
Kirsi Kalpala	Pfizer
Nan Bing	Pfizer
Xinli Hu	Pfizer
Jorge Esparza Gordillo	GSK
570 Nina Mars	University of Helsinki / FIMM

Pulmonology Group

Tarja Laitinen	LEAD:Tampere
Margit Pelkonen	Kuopio
Paula Kauppi	Helsinki
575 Hannu Kankaanranta	Tampere

	Terttu Harju	Oulu
	Nizar Smaoui	AbbVie
	David Close	AstraZeneca
	Steven Greenberg	Celgene
580	Hubert Chen	Genentech
	Natalie Bowers	Genentech
	John Michon	Genentech
	Vinay Mehta	Merck
	Jo Betts	GSK
585	Soumitra Ghosh	GSK

Cardiometabolic Diseases Group

	Veikko Salomaa	Lead: THL
	Teemu Niiranen	THL
	Markus Juonala	Turku
590	Kaj Metsärinne	Turku
	Mika Kähönen	Tampere
	Juhani Junttila	Oulu
	Markku Laakso	Kuopio
	Jussi Pihlajamäki	Kuopio
595	Juha Sinisalo	Helsinki
	Marja-Riitta Taskinen	Helsinki
	Tiinamaija Tuomi	Helsinki
	Jari Laukkanen	Keski-Suomen Keskussairaala
	Ben Challis	AstraZeneca
600	Keith Usiskin	Celgene
	Andrew Peterson	Genentech
	Julie Hunkapiller	Genentech
	Natalie Bowers	Genentech
	John Michon	Genentech
605	Dorothee Diogo	Merck
	Dermot Reilly	Merck
	Audrey Chu	Merck
	Vinay Mehta	Merck
	Jaakko Parkkinen	Pfizer
610	Melissa Miller	Pfizer
	Anthony Muslin	Sanofi
	Dawn Waterworth	GSK

Oncology Group

	Heikki Joensuu	Lead: Helsinki
615	Tuomo Meretoja	Helsinki

30/35

	Olli Carpen	Helsinki
	Lauri Aaltonen	Helsinki
	Annika Auranen	Tampere
	Peeter Karihtala	Oulu
620	Saila Kauppila	Oulu
	Päivi Auvinen	Kuopio
	Klaus Elenius	Turku
	Relja Popovic	AbbVie
	Jeffrey Waring	AbbVie
625	Bridget Riley-Gillis	AbbVie
	Anne Lehtonen	AbbVie
	Athena Matakidou	AstraZeneca
	Jennifer Schutzman	Genentech
	Julie Hunkapiller	Genentech
630	Natalie Bowers	Genentech
	John Michon	Genentech
	Vinay Mehta	Merck
	Andrey Loboda	Merck
	Aparna Chhibber	Merck
635	Heli Lehtonen	Pfizer
	Stefan McDonough	Pfizer
	Marika Crohns	Sanofi
	Diptee Kulkarni	GSK

Ophthalmology Group

640	Kai Kaarniranta	Lead: Kuopio
	Joni Turunen	HUS/ Secretary
	Terhi Ollila	HUS
	Sanna Seitsonen	HUS
	Hannu Uusitalo	Tampere
645	Vesa Aaltonen	Turku
	Hannele Uusitalo-Järvinen	PSHP
	Marja Luodonpää	Oulu
	Nina Hautala	Oulu
	Heiko Runz	Biogen
650	Erich Strauss	Genentech
	Natalie Bowers	Genentech
	Hao Chen	Genentech
	John Michon	Genentech
	Anna Podgornaia	Merck
655	Vinay Mehta	Merck
	Dorothee Diogo	Merck

Joshua Hoffman   GSK

Dermatology Group

Kaisa Tasanen	Oulu
Laura Huilaja	Oulu
Katariina Hannula-Jouppi	HUS
Teea Salmi	Tampere
Sirkku Peltonen	Turku
Leena Koulu	Turku
Ilkka Harvima	Kuopio
Kirsi Kalpala	Pfizer
Ying Wu	Pfizer
David Choy	Genentech
John Michon	Genentech
Nizar Smaoui	AbbVie
Fedik Rahimov	AbbVie
Anne Lehtonen	AbbVie
Dawn Waterworth	GSK

FinnGen Teams

Administration Team

Anu Jalanko	University of Helsinki / FIMM
Risto Kajanne	University of Helsinki / FIMM
Ulrike Lyhs	University of Helsinki / FIMM

Communication

Mari Kaunisto	University of Helsinki / FIMM

Analysis Team

Justin Wade Davis	Abbvie
Bridget Riley-Gillis	Abbvie
Danjuma Quarless	Abbvie
Slavé Petrovski	Astra Zeneca
Jimmy Liu	Biogen
Chia-Yen Chen	Biogen
Paola Bronson	Biogen
Robert Yang	Celgene
Joseph Maranville	Celgene
Shameek Biswas	Celgene
Diana Chang	Genentech

	Julie Hunkapiller	Genentech
	Tushar Bhangale	Genentech
695	Natalie Bowers	Genentech
	Dorothee Diogo	Merck
	Emily Holzinger	Merck
	Padhraig Gormley	Merck
	Xulong Wang	Merck
700	Xing Chen	Pfizer
	Åsa Hedman	Pfizer
	Joshua Hoffman	GSK
	Clarence Wang	Sanofi
	Ethan Xu	Sanofi
705	Franck Auge	Sanofi
	Clement Chatelain	Sanofi
	Mitja Kurki	University of Helsinki / FIMM/ Broad Institute
	Samuli Ripatti	University of Helsinki / FIMM
	Mark Daly	University of Helsinki / FIMM
710	Juha Karjalainen	University of Helsinki / FIMM/ Broad Institute
	Aki Havulinna	University of Helsinki / FIMM
	Anu Jalanko	University of Helsinki / FIMM
	Kimmo Palin	University of Helsinki
	Priit Palta	University of Helsinki / FIMM
715	Pietro della Briotta Parolo	University of Helsinki / FIMM
	Wei Zhou	Broad Institute
	Susanna Lemmelä	University of Helsinki / FIMM
	Manuel Rivas	University of Stanford
	Jarmo Harju	University of Helsinki / FIMM
720	Aarno Palotie	University of Helsinki / FIMM
	Arto Lehisto	University of Helsinki / FIMM
	Andrea Ganna	University of Helsinki / FIMM
	Vincent Llorens	University of Helsinki / FIMM
	Antti Karlsson	Auria BB / Univ. of Turku /VSSHP
725	Kati Kristiansson	THL BB / THL
	Mikko Arvas	Finnish Red Cross Blood Service BB /FHRB
	Kati Hyvärinen	Finnish Red Cross Blood Service BB /FHRB
	Jarmo Ritari	Finnish Red Cross Blood Service BB /FHRB
	Tiina Wahlfors	Finnish Red Cross Blood Service BB /FHRB
730	Miika Koskinen	Helsinki BB/HUS/Univ Hosp Districts
	Olli Carpen	Helsinki BB/HUS/Univ Hosp Districts
	Johannes Kettunen	Borealis BB/Univ. of Oulu/PPSHP
	Katri Pylkäs	Borealis BB/Univ. of Oulu/PPSHP
	Marita Kalaoja	Borealis BB/Univ. of Oulu/PPSHP
735	Minna Karjalainen	Borealis BB/Univ. of Oulu/PPSHP

	Tuomo Mantere	Borealis BB/Univ. of Oulu/PPSHP
	Eeva Kangasniemi	Tampere BB/Univ Tampere/PSHP
	Sami Heikkinen	Eastern Finland BB/UEF/PSSHP
	Arto Mannermaa	Eastern Finland BB/UEF/PSSHP
740	Eija Laakkonen	Central Finland BB /UJy/KSSHP
	Juha Kononen	Central Finland BB /UJy/KSSHP

Sample Collection Coordination

	Anu Loukola	Helsinki BB/HUS/Univ Hosp Districts

Sample Logistics

745	Päivi Laiho	THL BB / THL
	Tuuli Sistonen	THL BB / THL
	Essi Kaiharju	THL BB / THL
	Markku Laukkanen	THL BB / THL
	Elina Järvensivu	THL BB / THL
750	Sini Lähteenmäki	THL BB / THL
	Lotta Männikkö	THL BB / THL
	Regis Wong	THL BB / THL

Registry Data Operations

	Kati Kristiansson	THL BB / THL
755	Hannele Mattsson	THL BB / THL
	Susanna Lemmelä	University of Helsinki / FIMM
	Tero Hiekkalinna	THL BB / THL
	Manuel González Jiménez	THL BB / THL

Genotyping

760	Kati Donner	University of Helsinki / FIMM

Sequencing Informatics

	Priit Palta	University of Helsinki / FIMM
	Kalle Pärn	University of Helsinki / FIMM
	Javier Nunez-Fontarnau	University of Helsinki / FIMM

765

Data Management and IT Infrastructure

	Jarmo Harju	University of Helsinki / FIMM
	Elina Kilpeläinen	University of Helsinki / FIMM
	Timo P. Sipilä	University of Helsinki / FIMM
	Georg Brein	University of Helsinki / FIMM
770	Alexander Dada	University of Helsinki / FIMM

Ghazal Awaisa   University of Helsinki / FIMM
Anastasia Shcherban University of Helsinki / FIMM
Tuomas Sipilä   University of Helsinki / FIMM

Clinical Endpoint Development

Hannele Laivuori   University of Helsinki / FIMM
Aki Havulinna   University of Helsinki / FIMM
Susanna Lemmelä   University of Helsinki / FIMM
Tuomo Kiiskinen   University of Helsinki / FIMM

Trajectory Team

Tarja Laitinen   Tampere University Hospital
Harri Siirtola   University of Tampere
Javier Gracia Tabuenca   University of Tampere

Biobank Directors

Lila Kallio   Auria Biobank
Sirpa Soini   THL Biobank
Jukka Partanen   Blood Service Biobank
Kimmo Pitkänen   Helsinki Biobank
Seppo Vainio   Northern Finland Biobank Borealis
Kimmo Savinainen   Tampere Biobank
Veli-Matti Kosma   Biobank of Eastern Finland
Teijo Kuopio   Central Finland Biobank